{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:18:30Z","timestamp":1781295510076,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR203309"],"award-info":[{"award-number":["NIHR203309"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012295","name":"NIHR Newcastle Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000774","name":"Newcastle University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003776","name":"Newcastle upon Tyne Hospitals NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jad.2025.119937","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T07:01:52Z","timestamp":1752822112000},"page":"119937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial"],"prefix":"10.1016","volume":"391","author":[{"given":"Michael","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timea","family":"Helter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumbini","family":"Azim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Fouweather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hindmarch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Morriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.A.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Weetman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Hamish","family":"McAllister-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.119937_bb0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11136-011-9927-2","article-title":"Development of a self-report measure of capability wellbeing for adults: the ICECAP-A","volume":"21","author":"Al-Janabi","year":"2012","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jad.2025.119937_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-021-03322-y","article-title":"Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study)","volume":"21","author":"Azim","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.119937_bb0015","doi-asserted-by":"crossref","first-page":"s28","DOI":"10.1192\/bjp.177.39.s28","article-title":"Client socio-demographic and service receipt inventory \u2013 European version: development of an instrument for international research: EPSILON study 5","volume":"177","author":"Chisholm","year":"2000","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119937_bb0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1192\/bjp.180.3.227","article-title":"Annual cost of bipolar disorder to UK society","volume":"180","author":"Das Gupta","year":"2002","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119937_bb0025","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"10.1016\/j.jad.2025.119937_bb0030","series-title":"An Introduction to the Bootstrap","author":"Efron","year":"1994"},{"key":"10.1016\/j.jad.2025.119937_bb0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy (New York)"},{"key":"10.1016\/j.jad.2025.119937_bb0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1176\/appi.ajp.2015.15060788","article-title":"Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression","volume":"173","author":"Fawcett","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119937_bb0045","doi-asserted-by":"crossref","DOI":"10.1192\/bjp.187.2.106","article-title":"A guide to cost-effectiveness acceptability curves","author":"Fenwick","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119937_bb0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"9","author":"Ferrari","year":"2022","journal-title":"Lancet Psychiat."},{"key":"10.1016\/j.jad.2025.119937_bb0055","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hec.3014","article-title":"Scoring the icecap-a capability instrument. Estimation of a UK general population tariff","volume":"24","author":"Flynn","year":"2015","journal-title":"Health Econ."},{"key":"10.1016\/j.jad.2025.119937_bb0060","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.161.3.564","article-title":"Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression","volume":"161","author":"Goldberg","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.119937_bb0065","doi-asserted-by":"crossref","DOI":"10.2196\/15188","article-title":"The true colours remote symptom monitoring system: a decade of evolution","volume":"22","author":"Goodday","year":"2020","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.jad.2025.119937_bb0070","doi-asserted-by":"crossref","DOI":"10.1007\/s11136-019-02393-5","article-title":"Capability instruments in economic evaluations of health-related interventions: a comparative review of the literature","author":"Helter","year":"2020","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jad.2025.119937_bb0075","series-title":"Unit Costs of Health and Social Care 2021","author":"Jones","year":"2021"},{"key":"10.1016\/j.jad.2025.119937_bb0080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.119937_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/archpsyc.60.3.261","article-title":"A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder","volume":"60","author":"Judd","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.119937_bb0090","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s13063-017-2247-2","article-title":"The effects of using the PReDicT test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial","volume":"18","author":"Kingslake","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.jad.2025.119937_bb0095","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1017\/S0924270800035547","article-title":"Stabilization in the treatment of mania, depression and mixed states","volume":"12","author":"Kupfer","year":"2000","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.jad.2025.119937_bb0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/ebmental-2021-300334","article-title":"Patient-reported outcome measures suitable for quality of life\/well-being assessment in multisectoral, multinational and multiperson mental health economic evaluations","volume":"25","author":"\u0141aszewska","year":"2022","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.jad.2025.119937_bb0105","series-title":"Statistical Analysis with Missing Data","author":"Little","year":"2002"},{"key":"10.1016\/j.jad.2025.119937_bb0110","doi-asserted-by":"crossref","DOI":"10.1177\/02698811241309622","article-title":"A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)","author":"McAllister-Williams","year":"2025","journal-title":"J. Psychopharmacol."},{"issue":"21","key":"10.1016\/j.jad.2025.119937_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/HBFC1953","article-title":"Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial","volume":"29","author":"McAllister-Williams","year":"2025","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.jad.2025.119937_bb0120","series-title":"Paying the Price: The Cost of Mental Health Care in England to 2026","author":"McCrone","year":"2008"},{"key":"10.1016\/j.jad.2025.119937_bb0125","series-title":"Managing Long-term Sickness Absence and Incapacity for Work","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"10.1016\/j.jad.2025.119937_bb0130","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.jad.2025.119937_bb0135","series-title":"NICE Health Technology evaluations: the manual","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"10.1016\/j.jad.2025.119937_bb0140","article-title":"Bipolar disorders: an update on critical aspects","volume":"48","author":"Oliva","year":"2025","journal-title":"Lancet Reg. Health - Europe"},{"key":"10.1016\/j.jad.2025.119937_bb0145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bdi.12213","article-title":"Economic evaluations in bipolar disorder: a systematic review and critical appraisal","volume":"16","author":"Pari","year":"2014","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2025.119937_bb0150","series-title":"HEQ (Health Economics Questionnaire), Version 08-09-2016","author":"Simon","year":"2016"},{"key":"10.1016\/j.jad.2025.119937_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.socscimed.2013.09.019","article-title":"Operationalising the capability approach for outcome measurement in mental health research","volume":"98","author":"Simon","year":"2013","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.jad.2025.119937_bb0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00127-020-01919-4","article-title":"Cost and quality-of-life impacts of community treatment orders (CTOs) for patients with psychosis: economic evaluation of the OCTET trial","volume":"56","author":"Simon","year":"2021","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.jad.2025.119937_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2351","article-title":"The costs of bipolar disorder in the United Kingdom","volume":"11","author":"Simon","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.jad.2025.119937_bb0170","doi-asserted-by":"crossref","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","author":"Stinnett","year":"1998","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.jad.2025.119937_bb0175","series-title":"Cost-of-illness Analysis. What Room in Health Economics? Health Policy (New York)","author":"Tarricone","year":"2006"},{"key":"10.1016\/j.jad.2025.119937_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110425","article-title":"Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study","volume":"112","author":"Tundo","year":"2022","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.119937_bb0185","series-title":"Manual Trimbos\/iMTA questionnaire for Costs associated with Psychiatric illness (TiC-P),Version September 2010","author":"van Hakkaart- Roijen","year":"2010"},{"key":"10.1016\/j.jad.2025.119937_bb0190","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12955-017-0825-3","article-title":"Psychometric validation of a multi-dimensional capability instrument for outcome measurement in mental health research (OxCAP-MH)","volume":"15","author":"Vergunst","year":"2017","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.jad.2025.119937_bb0195","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2025.119937_bb0200","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jad.2011.06.016","article-title":"Annual cost of managing bipolar disorder to the UK healthcare system","volume":"133","author":"Young","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119937_bb0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biopsych.2004.03.013","article-title":"Pramipexole for bipolar II depression: a placebo-controlled proof of concept study","volume":"56","author":"Zarate","year":"2004","journal-title":"Biol. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725013795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725013795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:17:22Z","timestamp":1779859042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725013795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"alternative-id":["S0165032725013795"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.119937","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.119937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119937"}}